Dialister in Microbiome of Cancer Patients: A Systematic Review and Meta-Analysis
Objectives: Dialister is the genus classified within Veillonellaceae family in Firmicutes phylum. Dialister genus has been detected in patients with oral infections and healthy people in their oral cavity, as well as in clinical samples in different parts of the body. Cancers are complex and multifactorial diseases and considered a global problem. End products of Dialister such as acetate, lactate and propionate seem to be important in the mechanism of carcinogenesis. Although it is reported that the composition of Dialister has changed in articles investigating the microbiome relationship with cancer patients, it is seen that it is not taken into consideration. The aim of this review was to investigate cancer studies in humans on the association of microbiome with composition changes in Dialister.
Methods: A systematic literature search was performed using in Pubmed. In vitro and animal studies were excluded. After database search, 510 articles were found. 484 article were excluded based on the exclusion criteria. The remaining 26 articles were identified and analysed for Dialister. Meta-Mar online software was used for metaanalysis results.
Results: The meta-analysis included 26 studies with 1649 control samples and 1961 cancer samples. Compared to healthy controls, Dialister were significantly elevated in samples from cancer patients (Hedges’g=0.907, p<0.05, 95%CI [13.19 - 16.746]. Statistical heterogeneity was found hihg (I2 =99.6%).
Conclusion: This review showed that a relationship between different cancer types and Dialister composition of microbiome. however, these data still seem very weak to reveal the Dialister and cancer relationship. Dialister can be an important genus especially in solid tumors but, more comprehensive and wider studies are needed to understand the relationship between Dialister and cancer. In addition, due to rapidly developing new bioinformatics analysis techniques, massive data should be added to public databases by the authors in studies of microbiome or microbiota disease relationship. Thus, it is valuable in terms of detecting different strains such as Dialister, which can be ignored by re-evaluating these data in the future.
1.Lochhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, et al. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol 2015;28:14–29. [CrossRef]
2. Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, et al. Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO Open 2018;3:e000285. [CrossRef]
3. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The Global Burden of Cancer 2013. JAMA Oncol 2015;1:505–27.
4. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al; CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023–75. [CrossRef]
5. Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol 2015;35 Suppl:S276–S304.
6. Miller JW, Hanson V, Johnson GD, Royalty JE, Richardson LC. From cancer screening to treatment: service delivery and referral in the National Breast and Cervical Cancer Early Detection Program. Cancer 2014;120 Suppl 16:2549–56. [CrossRef]
7. Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, et al. Artificial intelligence in cancer imaging: Clinical challenges and applications. CA Cancer J Clin 2019;69:127–57.
8. Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, et al. Gut microbiota and cancer: from pathogenesis to therapy. Cancers (Basel) 2019;11:38. [CrossRef]
9. Bastiaanssen TFS, Cowan CSM, Claesson MJ, Dinan TG, Cryan JF. Making sense of … the microbiome in psychiatry. Int J Neuropsychopharmacol 2019;22:37–52. [CrossRef]
10. Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome 2015;3:31. [CrossRef]
11. Shetty SA, Hugenholtz F, Lahti L, Smidt H, de Vos WM. Intestinal microbiome landscaping: insight in community assemblage and implications for microbial modulation strategies. FEMS Microbiol Rev 2017;41:182–99. [CrossRef]
12. Milani C, Duranti S, Bottacini F, Casey E, Turroni F, Mahony J, et al. The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota. Microbiol Mol Biol Rev 2017;81:e00036–17.
13. Wade WG. Dialister. In: Whitman WB, Rainey F, Kämpfer P, Trujillo M, Chun J, DeVos P, editors. Bergey's Manual of Systematics of Archaea and Bacteria. Wiley Online Library; 2015.
14. Downes J, Munson M, Wade WG. Dialister invisus sp. nov., isolated from the human oral cavity. Int J Syst Evol Microbiol 2003;53:1937–40. [CrossRef]
15. Morio F, Jean-Pierre H, Dubreuil L, Jumas-Bilak E, Calvet L, Mercier G, et al. Antimicrobial susceptibilities and clinical sources of Dialister species. Antimicrob Agents Chemother 2007;51:4498–501. [CrossRef]
16. Jumas-Bilak E, Jean-Pierre H, Carlier JP, Teyssier C, Bernard K, Gay B, et al. Dialister micraerophilus sp. nov. and Dialister propionicifaciens sp. nov., isolated from human clinical samples. Int J Syst Evol Microbiol 2005;55:2471–8. [CrossRef]
17. Morotomi M, Nagai F, Sakon H, Tanaka R. Dialister succinatiphilus sp. nov. and Barnesiella intestinihominis sp. nov., isolated from human faeces. Int J Syst Evol Microbiol 2008;58:2716–20.
18. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777–84. [CrossRef]
19. Wang A, Ling Z, Yang Z, Kiela PR, Wang T, Wang C, et al. Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS One 2015;10:e0126312. [CrossRef]
20. Walther-António MR, Chen J, Multinu F, Hokenstad A, Distad TJ, Cheek EH, et al. Potential contribution of the uterine microbiome in the development of endometrial cancer. Genome Med 2016;8:122. [CrossRef]
21. Sims TT, Colbert LE, Zheng J, Delgado Medrano AY, Hoffman KL, Ramondetta L, et al. Gut microbial diversity and genuslevel differences identified in cervical cancer patients versus healthy controls. Gynecol Oncol 2019;155:237–44. [CrossRef]
22. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One 2012;7:e39743. [CrossRef]
23. Hibberd AA, Lyra A, Ouwehand AC, Rolny P, Lindegren H, Cedgård L, et al. Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. BMJ Open Gastroenterol 2017;4:e000145. [CrossRef]
24. Xu K, Jiang B. Analysis of mucosa-associated microbiota in colorectal cancer. Med Sci Monit 2017;23:4422–30. [CrossRef]
25. Flemer B, Warren RD, Barrett MP, Cisek K, Das A, Jeffery IB, et al. The oral microbiota in colorectal cancer is distinctive and predictive. Gut 2018;67:1454–63. [CrossRef]
26. Zhang Y, Yu X, Yu E, Wang N, Cai Q, Shuai Q, et al. Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study. BMC Microbiol 2018;18:92. [CrossRef]
27. Loke MF, Chua EG, Gan HM, Thulasi K, Wanyiri JW, Thevambiga I, et al. Metabolomics and 16S rRNA sequencing of human colorectal cancers and adjacent mucosa. PLoS One 2018;13:e0208584. [CrossRef]
28. Chen X, Winckler B, Lu M, Cheng H, Yuan Z, Yang Y, et al. Oral microbiota and risk for esophageal squamous cell carcinoma in a high-risk area of China. PLoS One 2015;10:e0143603.
29. Elliott DRF, Walker AW, O'Donovan M, Parkhill J, Fitzgerald RC. A non-endoscopic device to sample the oesophageal microbiota: a case-control study. Lancet Gastroenterol Hepatol 2017;2:32–42. [CrossRef]
30. Castaño-Rodríguez N, Goh KL, Fock KM, Mitchell HM, Kaakoush NO. Dysbiosis of the microbiome in gastric carcinogenesis. Sci Rep 2017;7:15957. [CrossRef]
31. Liang W, Yang Y, Wang H, Wang H, Yu X, Lu Y, et al. Gut microbiota shifts in patients with gastric cancer in perioperative period. Medicine (Baltimore). 2019;98:e16626. [CrossRef]
32. Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut 2018;67:1024–32. [CrossRef]
33. Ling Z, Shao L, Liu X, Cheng Y, Yan C, Mei Y, et al. Regulatory T cells and plasmacytoid dendritic cells within the tumor microenvironment in gastric cancer are correlated with gastric microbiota dysbiosis: a preliminary study. Front Immunol 2019;10:533. [CrossRef]
34. Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, et al. Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer. EBioMedicine 2019;40:336–48. [CrossRef]
35. Gong H, Shi Y, Zhou X, Wu C, Cao P, Xu C, et al. Microbiota in the throat and risk factors for laryngeal carcinoma. Appl Environ Microbiol 2014;80:7356–63. [CrossRef]
36. Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A, RodríguezHilario A, González H, Bondy J, et al. 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment. Oncotarget 2016;7:51320–34. [CrossRef]
37. Gong H, Shi Y, Xiao X, Cao P, Wu C, Tao L, et al. Alterations of microbiota structure in the larynx relevant to laryngeal carcinoma. Sci Rep 2017;7:5507. [CrossRef]
38. Zhao H, Chu M, Huang Z, Yang X, Ran S, Hu B, et al. Variations in oral microbiota associated with oral cancer. Sci Rep 2017;7:11773. [CrossRef]
39. Börnigen D, Ren B, Pickard R, Li J, Ozer E, Hartmann EM, et al. Alterations in oral bacterial communities are associated with risk factors for oral and oropharyngeal cancer. Sci Rep 2017;7:17686. [CrossRef]
40. Yang CY, Yeh YM, Yu HY, Chin CY, Hsu CW, Liu H, et al. Oral microbiota community dynamics associated with oral squamous cell carcinoma staging. Front Microbiol 2018;9:862.
41. Zhang L, Liu Y, Zheng HJ, Zhang CP. The oral microbiota may have influence on oral cancer. Front Cell Infect Microbiol 2020;9:476. [CrossRef]
42. Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, et al. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. Int J Cancer 2018;142:769–78.
43. Liu Y, O'Brien JL, Ajami NJ, Scheurer ME, Amirian ES, Armstrong G, et al. Lung tissue microbial profile in lung cancer is distinct from emphysema. Am J Cancer Res 2018;8:1775–87.
44. Liu F, Li J, Guan Y, Lou Y, Chen H, Xu M, et al. Dysbiosis of the gut microbiome is associated with tumor biomarkers in lung cancer. Int J Biol Sci 2019;15:2381–92. [CrossRef]
45. Thomas S, Izard J, Walsh E, Batich K, Chongsathidkiet P, Clarke G, et al. The Host microbiome regulates and maintains human health: a primer and perspective for non-microbiologists. Cancer Res 2017;77:1783–812. [CrossRef]
46. Borges-Canha M, Portela-Cidade JP, Dinis-Ribeiro M, LeiteMoreira AF, Pimentel-Nunes P. Role of colonic microbiota in colorectal carcinogenesis: a systematic review. Rev Esp Enferm Dig 2015;107:659–71. [CrossRef]
47. Mikó E, Kovács T, Sebő É, Tóth J, Csonka T, Ujlaki G, et al. Microbiome-microbial metabolome-cancer cell interactions in breast cancer-familiar, but unexplored. Cells 2019;8:293.
48. Ratajczak W, Rył A, Mizerski A, Walczakiewicz K, Sipak O, Laszczyńska M. Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs). Acta Biochim Pol 2019;66:1–12. [CrossRef]
49. Casanova MR, Azevedo-Silva J, Rodrigues LR, Preto A. Colorectal cancer cells increase the production of short chain fatty acids by Propionibacterium freudenreichii impacting on cancer cells survival. Front Nutr 2018;5:44. [CrossRef]
50. Comerford SA, Huang Z, Du X, Wang Y, Cai L, Witkiewicz AK, et al. Acetate dependence of tumors. Cell 2014;159:1591–602.
51. Goodwin ML, Pennington Z, Westbroek EM, Cottrill E, Ahmed AK, Sciubba DM. Lactate and cancer: a "lactatic" perspective on spinal tumor metabolism (part 1). Ann Transl Med 2019;7:220. [CrossRef]
52. Bindels LB, Porporato P, Dewulf EM, Verrax J, Neyrinck AM, Martin JC, et al. Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br J Cancer 2012;107:1337–44.
53. Valles-Colomer M, Falony G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol 2019;4:623–32. [CrossRef]
54. Naderpoor N, Mousa A, Gomez-Arango LF, Barrett HL, Dekker Nitert M, de Courten B. Faecal microbiota are related to ınsulin sensitivity and secretion in overweight or obese adults. J Clin Med 2019;8:452. [CrossRef]
55. Chen Z, Qi J, Wei Q, Zheng X, Wu X, Li X, Liao Z, Lin Z, Gu J. Variations in gut microbial profiles in ankylosing spondylitis: disease phenotype-related dysbiosis. Ann Transl Med 2019;7:571. [CrossRef]
56. Yost S, Stashenko P, Choi Y, Kukuruzinska M, Genco CA, Salama A, et al. Increased virulence of the oral microbiome in oral squamous cell carcinoma revealed by metatranscriptome analyses. Int J Oral Sci 2018;10:32. [CrossRef]
57. Saleh R, Elkord E. FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. Cancer Lett 2020;490:174–85.
58. Jimma F, Takeda Y, Kaneda K, Wakabayashi I. Induction of Foxp3 expression in T cells by cellulose acetate beads in vitro. J Clin Apher 2010;25:216–22. [CrossRef]
59. Angelin A, Gil-de-Gómez L, Dahiya S, Jiao J, Guo L, Levine MH, et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab 2017;25:1282–93.e7. [CrossRef]